Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Price analytics
Returns
1 day
0.0%
1 week
0.0%
1 month
-16.7%
3 months
-28.6%
6 months
0.0%
1 year
25.0%
3 years
-59.9%
Risk
Volatility (1y ann.)
171.6%
Beta vs ASX 200
0.90
Sharpe (1y)
0.91
VaR 95% (1-day)
-16.7%
Max drawdown (1y)
-50.0%
Off 1-year high
-37.5%
Technicals
RSI(14)
33
vs 50DMA
-17.2%
vs 200DMA
-16.3%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value56.8
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
42
Price / Sales
0
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health30.6
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
0
Debt / Equity
55
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum33.3
6-month return vs ASX 200
83
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
33
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).